Özgeçmiş

KİŞİSEL BİLGİLER

  • Doğum Tarihi : 1980
  • Kan Gurubu : A Rh+
  • Birimi : Bucak Sağlık Yüksekokulu    
  • Anabilim Dalı :
AKADEMİK ÖZGEÇMİŞ

  • Yabancı Dil : İngilizce
  • İlk Okul : Şenlik İlköğretim Okulu, Keçiören, ANKARA (1992)
  • Orta Okul : Fatih Sultan Mehmet Lisesi, Keçiören, ANKARA (1995)
  • Lise : Fatih Sultan Mehmet Lisesi, Keçiören, ANKARA (1997)
  • Lisans : Akdeniz Üniversitesi
  • Lisans Fakülte : Fen-Edebiyat Fakültesi
  • Lisans Bölüm : Biyoloji Anabili Dalı (2002)
  • Y.Lisans : Akdeniz Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik ABD
  • Y.Lisans Dal : Tıbbi Genetik Bilim Dalı (2005)
  • Doktora : Akdeniz Üniversitesi, Tıp Fakültesi,Tıbbi Biyoloji ve Genetik ABD
  • Doktora Dal : Tıbbi Genetik Bilim Dalı
  • (2011)
ÖZGEÇMİŞ

Adı, Soyadı                            : Çiğdem AYDIN ACAR

Doğum Tarihi ve Yeri             : 12.07.1980, Ankara

Elektronik posta                   : cacar@mehmetakif.edu.tr

Eğitim Durumu

Doktora         :2005 – 2011 Tıbbi Genetik Programı, Akdeniz Üniversitesi, Tıp         Fakültesi, Tıbbi          Biyoloji ve Genetik Anabilim Dalı, Antalya.

Y. Lisans       :2003 – 2005 Tıbbi Genetik Programı, Akdeniz Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve        Genetik Anabilim Dalı, Antalya.

Lisans          :1998 – 2002 Biyoloji Bölümü, Fen-Edebiyat Fakültesi, Akdeniz Üniversitesi, Antalya. 

Akademik Deneyimi

Yrd.Doç.Dr                :  2015 -  ......   Hemşirelik Bölümü, Bucak Sağlık Yüksekokulu Mehmet Akif Ersoy Üniversitesi, Burdur

Bölüm Başkanlığı    : 2015 - ...... Hemşirelik Bölüm Başkanlığı, Bucak Sağlık Yüksekokulu, Mehmet Akif Ersoy Üniversitesi, Burdur

Bölüm Başkanlığı    : 2015 - ...... Çocuk Gelişimi Bölüm Başkanlığı (vekaleten), Bucak Sağlık Yüksekokulu, Mehmet Akif Ersoy Üniversitesi, Burdur

Uzman Biyolog        : 2011-2015    Genetik Hastalıklar Tanı Merkezi, Akdeniz Üniversitesi, Tıp Fakültesi Hastanesi , Antalya

Arş.Gör                     : 2004-2011 Tıbbi Biyoloji ve Genetik Anabilim Dalı - Gen ve Hücre Tedavisi Ünitesi, Akdeniz Üniversitesi Tıp Fakültesi, Antalya

SCI’e kayıtlı dergilerdeki yayınlar

  • Aydin C, Cetin Z, Manguoglu E, Tayfun F, Altiok-Clark O, Kupesiz A. Evaluation of ETV6/RUNX1 fusion and additional abnormalities involving ETV6 and/or RUNX1 genes using FISH technique in patients with childhood Acute Lymphoblastic Leukemia. Indian J Hematol Blood Transfus. 06/2015. DOI: 10.1007/s12288-015-0557-7

     

  • Kahraman S, Aydin C, Elpek GO, Dirice E, Sanlioglu AD. Diabetes-resistant NOR mice are more severely affected by streptozotocin compared to the diabetes-prone NOD mice: correlations with liver and kidney GLUT2 expressions. J Diabetes Res. 2015; 2015: 450128.

     

  • Bisgin A, Kargi A, Yalcin AD, Aydin C, Ekinci D, Savas B, Sanlioglu S. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer. 2012 Feb 7;12:58.

     

  • Dirice E, Kahraman S, Elpek GO, Aydin C, Balci MK, Omer A, Sanlioglu S, Sanlioglu AD. TRAIL and DcR1 expressions are differentially regulated in the pancreatic islets of STZ- versus CY-applied NOD mice. Exp Diabetes Res. 2011;2011:625813.

     

  • Aydin C, Sanlioglu AD, Bisgin A, Yoldas B, Dertsiz L, Karacay B, Griffith TS, Sanlioglu S. NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. BMC Cancer. 2010 Oct 27;10:584.

     

  • Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S. TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskeletal Disorders. 2010, 11:192

     

  • Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Human Gene Therapy. 2007 Jan; 18: 39-50.

     

  • Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 25;5(1):54

     

  • Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E and Sanlioglu S. Fundamental Principals of Tumor Necrosis Factor-alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer. 2004 44: 199-211.

  • SCI’e kayıtlı olmayan dergilerdeki yayınlar

  • Aydin C, Salim O, Yucel OK, Undar L, Karauzum SB. inv(4)(p13q13) in patient with Essential Thrombocythemia: A case report. Hematology/Oncology and Stem Cell Therapy. 2015 Apr 28. doi: 10.1016/j.hemonc.2015.04.003.

     

  • Aydin C, Cetin Z, Salim O, Yucel OK, Undar L, Berker Karauzum S.Previously Unreported Chromosomal Aberrations of t(3;3)(q29;q23), t(4;11)(q21;q23), and t(11;18)(q10;q10) in a Patient with Accelerated Phase Ph+ CML. Case Rep Genet. 2014;2014:582016.

  •  

    Uluslararası (SCI’e kayıtlı dergilerde yayınlanan bildiriler)

     

    1-    Kahraman S, Dirice E, Elpek GO, Aydin C, Balci MK, Omer A, Sanlioglu S, Sanlioglu AD. Pancreatic acinar cells respond differentially to diabetic agents Streptozotocin and Cyclophosphamid. Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy. Human Gene Therapy. Oct 25-29, 2012 23; 10:A79-A79 Versailles, FRANCE

    2-    Kahraman S, Aydin C, Elpek GO, Dirice E, Sanlioglu AD. Diabetogenic response to streptozotocin varies among NOD and NOR mice. Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy. Human Gene Therapy. Oct 25-29, 2012 23; 10:A77-A77 Versailles, FRANCE

    3-    Bisgin A, Sanlioglu AD, Yoldas B, Aydin C, Yazisiz V, Tuzuner S, Gorczynski  RM, Akdis CA, Terzioglu E, Sanlioglu S. Trail profile of synoviocytes and peripheral blood lymphocytes of rheumatoid arthritis patients. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy. Human Gene Therapy. Oct 22-25, 2010 21; 10: 1448-49 Milan, ITALY

    4-    Bisgin A, Terzioglu E, Erbasan F, Aydin C, Sanlioglu S. The importance of sTRAIL in patients with rheumatoid arthritis. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy. Human Gene Therapy. Oct 22-25, 2010 21; 10: 1461 Milan, ITALY

    5-    Aydin C, Bisgin A, Sanlioglu AD, Pestereli E, Erdogan G, Ozbudak IH, Simsek T, Sanlioglu S. Endometrial hyperplasia features distinctive TRAIL and TRAIL receptor expression profiles. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy. Human Gene Therapy. Oct 22-25, 2010 21; 10: 1462-63 Milan, ITALY

    6-    Aydin C, Bisgin A, Sanlioglu AD, Pestereli E, Erdogan G, Ozbudak IH, Simsek T, Sanlioglu S. Distinctive expression profiles of TRAIL and TRAIL receptors in patients with endometrial carcinoma. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy. Human Gene Therapy. Oct 22-25, 2010 21; 10: 1462 Milan, ITALY

    7-    Hapil FZ, Bisgin A, Aydin C, Undar L, Sanlioglu AD, Sanlioglu S. The outcome of TRAIL presentation on T cells in patients with multiple myeloma.  18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy. Human Gene Therapy. Oct 22-25, 2010 21; 10: 1462 Milan, ITALY

    8-    Bisgin A, Kargi A, Yalcin A, Aydin C, Savas B, Sanlioglu S. Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research. Human Gene Therapy. Nov 21-25, 2009 20; 11: 1417 Hannover, GERMANY

    9-    Bisgin A, Terzioglu E, Aydin C, Yazisiz V, Balci N, Bagci H, Gorczynski R, Akdis C, Sanlioglu S. TRAIL death receptor-4 and decoy receptors expression on CD8+T cells correlate with the disease severity in rheumatoid arthritis patients. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research. Human Gene Therapy. Nov 21-25, 2009 20; 11: 1471 Hannover, GERMANY

    10-Kahraman S, Hapil FZ, Aydin C, Bisgin A, Dirice E, Griffith TS, Sanlioglu AD, Sanlioglu S. Tracing of the fate of allogeneic islet grafts via CCD camera. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research. Human Gene Therapy. Nov 21-25, 2009. 20; 11: 1479 Hannover, GERMANY

    11-Bisgin A, Aydin C, Erbasan F, Terzioglu E, Sanlioglu S. Diagnostic significance of serum sTRAIL in rheumatoid arthritis Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research. Human Gene Therapy. Nov 21-25, 2009. 20; 11: 1494 Hannover, GERMANY

    12-Bisgin A, Terzioglu E, Aydin C, Yazisiz V, Balci N, Bagci H, Gorczynski R. M, Akdis C. A, Sanlioglu S. Rheumatoid Arthritis disease activity is correlated with TRAIL death receptor-4 and decoy receptor expresions on CD8+ T cells. 34th Congress of the Federation-of-European-Biochemical-Societies. FEBS Journal. Jul 04-09,2009.276 :259 Prague, CZECH REPUBLIC

    13-Bisgin A, Kargi A, Yalcin A, Aydin C, Savas B, Sanlioglu S. Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. 34th Congress of the Federation-of-European-Biochemical-Societies. FEBS Journal. Jul 04-09,2009; 276  Pages: 301-302 Prague, CZECH REPUBLIC

    14-Aydin C, Ozbudak O, Dertsiz L, Ozbilim G, Akdis CA, Sanlioglu S. DcR2 siRNA approach defeats TRAIL resistance in lung cancer cells. 31st Congress of the Federation-of-European-Biochemical-Societies (FEBS) FEBS Journal. Jun 24-29,2006 273;1: 133 Istanbul, TURKEY

     

    Uluslararası Kongrelerde yayınlanan bildiriler

     

    1-    Kahraman S, Elpek GO, Aydin Acar C, Dirice E, Sanlioglu AD. Non-obese diabetes resistant (NOR) mice are extremely susceptible to the toxic effects of streptozotocin reflected by high Glut2 expressions in pancreas and liver. Abstract PP-07. Beta Cells in Health and Disease. May 21-22, 2014. Kocaeli, Turkey.

    2-    Kahraman S, Aydin C, Elpek GO, Dirice E, Sanlioglu AD. Differential Expression of GLUT2 in Pancreatic Islets Affects Streptozotocin Sensitivity in NOD and NOR mice. Abstract P-2177. 73 rd American Diabetes Association (ADA) Scientific Sessions. June 21-25, 2013. Chicago, IL.

    3-    Aydin Acar C, Salim O, Cetin Z, Yucel OK, Timuragaoglu A, Karadogan I, Undar L, Berker S. Cytogenetic and molecular cytogenetic findings in chronic lymphocytic leukemıa; A single center experience. Abstract P306. III. International Eurasian Hematology Congress. October 17-21, 2012. Antalya, Turkey.

    4-    Berker S, Salim O, Cetin Z, Aydin Acar C, Yucel OK, Timuragaoglu A, Karadogan I, Undar L. Analysis of molecular cytogenetic markers and clinical outcome in chronic lymphocytic leukemia and multiple myeloma with 17p deletion; A single center experience. Abstract P341. III. International Eurasian Hematology Congress. October 17-21, 2012. Antalya, Turkey.

    5-    Cetin Z,  Salim O, Aydin Acar C, Yucel OK, Undar L, Berker S. Additional t(3;3)(q29;q23), t(4;11)(q21;q23), t(11;18)(q10;q10) translocations in a patient with chronic phase Ph+ CML. Abstract P345. III. International Eurasian Hematology Congress. October 17-21, 2012, Antalya, Turkey.

    6-    Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA, Sanlioglu S. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Abstract P-4. Gene Therapy Symposium . 2-3 November 2007. Istanbul, Turkey.

    7-    Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E, Sanlioglu S.Fundamental principles of tumor necrosis factor alpha gene therapy approach and implications for patients with lung carcinoma. Abstract P-8. Gene Therapy Symposium . 2-3 November 2007. Istanbul, Turkey.

    8-    Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA, Sanlioglu S. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Abstract P103. XIV Annual Congress of the European Society of Gene Therapy. 9-12 November 2006. Athens, Greece.

    İLGİ ALANLARI

    Tıbbi Genetik

    Gen Tedavi

    Tıbbi Biyoloji

    Yayınlar ve Faaliyetler

    YAYINLAR

    SCI, SSCI ve AHCI tarafından taranan dergilerde yayımlanan teknik not, editöre mektup, tartışma, vaka takdimi ve özet türünden yayınlar dışındaki makale
    1- Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. (2012)
    2- Diabetes-resistant NOR Mice are more severely affected by stretozotocin compared to the diabetes-prone NOD mice: Correlations with Liver and Kidney GLUT2 Expressions (2015)
    3- Evaluation of ETV6/RUNX1 Fusion and Additional Abnormalities Involving ETV6 and/or RUNX1 Genes Using FISH Technique in Patients with Childhood Acute Lymphoblastic Leukemia (2015)
    4- TRAIL and DcR1 Expressions Are Differentially Regulated in the Pancreatic Islets of STZ- versus CY-Applied NOD Mice (2011)
    5- NF-kappa B targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL (2010)
    6- TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 Expression on CD8(+) T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis (2010)
    7- Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells (2007)
    8- Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells (2005)
    9- Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma (2004)
    SCI, SSCI ve AHCI dışındaki indeks ve özler tarafından taranan dergilerde yayımlanan teknik not, editöre mektup, tartışma, vaka takdimi ve özet türünden yayın
    1- Previously Unreported Chromosomal Aberrations of t(3;3)(q29;q23), t(4;11)(q21;q23), and t(11;18)(q10;q10) in a Patient with Accelerated Phase Ph+ CML (2014)
    2- inv (4)(p13q13) in patient with essential thrombocythemia: A case report (2015)
    Ulusal kongre, sempozyum, panel gibi bilimsel toplantılarda sunularak, programda yer alan poster bildiri
    1- Kronik faz Ph+ KML olgusunda gözlenen t(3;3)(q29;q23), t(4;11)(q21;q23), t(11;18)(q10;q10) translokasyonları (2012)
    2- 17p delesyonuna sahip multiple myeloma ve kronik lenfositer lösemi tanılı olgularda moleküler sitogenetik markırlar ve terapi sonuçlarının incelenmesi (2012)
    3- Kronik lenfositer lösemili hastalarda sitogenetik ve moleküler sitogenetik bulgular; Tek merkez deneyimi (2012)
    4- Endometrium karsinomunda ölümcül TRAIL ligand ve reseptör ekspresyon profilinin tümör evreleri ile ilişkilerinin belirlenmesi (2012)
    5- inv(4)(p13q13) kromozom anomalisine sahip esansiyel trombositemi tanılı olgu sunumu (2013)
    6- Çocukluk çağı akut lenfoblastik lösemili hastalarda floresan in situ hibridizasyon ile TEl/AML1 füzyonu ve TEL-AML1 genlerini içeren ek anomalilerin değerlendirilmesi (2013)
    7- Differential expression of GLUT2 in pancreatic islets affects streptozotocin sensitivity in NOD and NOR mice (2013)
    8- Diyabete dirençli NOR farelerin pankreas ve karaciğerlerinde yüksek GLUT2 ekspresyonu, diyabetik ajan streptozotosine karşı aşırı duyarlılık nedenidir (2014)
    9- Akut Promiyelositik lösemi olgusunda ilk kez tanımlanan klonal ek sitogenetik bozukluk (2014)
    10- FLT3-ITD ve/veya FLT3-D835 ve/veya NPM1 pozitif akut myeloid lösemi olguları:Tek Merkez deneyimi (2014)
    11- "Monozomi 7 MDS (RAEB)/PNH hastalığı": Hipometilasyon?, Kompleman İnhibisyonu?, Allojenik Kök Hücre Nakli? (2014)
    12- Plazmasitom ile prezente olan IgD lambda miyelom (2014)
    13- Monozomi 7'ye eşlik eden 7 numaralı kromozom orjinli ring/marker kromozoma sahip MDS-RAEB-2 Tanılı bir olgu sunumu (2014)
    14- Kronik lenfositik lösemili olgularda mdm2 onkogeninin aktivasyonunun belirlenmesi (2014)
    15- NOD (Non-Obese Diabetic) Farelerde Streptozotosin veya Siklofosfamid ile Hızlandırılmış Tip 1 Diyabet Gelişim Sürecinde Pankreatik Asinar Hücrelerde Farklı TRAIL Ligand ve Reseptör Ekspresyon Paternleri. (2011)
    16- Non-Obese Diabetic (NOD) farelerde streptozotosin veya siklofosfamid ile indüklenen diyabette T1D’in moleküler patogenezinin aydınlatılmasına yönelik bulgular. (2010)
    17- Serum sTRAIL konsantrasyonunun romatoid artrit tanısındaki yeri. (2009)
    18- Gene therapy mediated apoptosis inducing approaches employing Ad5hTRAIL and a DCR2 siRNA strategy in lung cancer patients. (2008)
    19- Gene therapy mediated apoptosis inducing approaches employing Ad5hTRAIL and a DCR2 siRNA strategy in lung cancer patients. (2008)
    20- A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. (2007)
    21- DcR2 siRNA yaklaşımı A549 akciğer kanser hücrelerini adenovirus aracılı TRAIL transferlerine duyarlı kılar. (2005)
    22- Akciğer kanserinde recombinant adenovirus aracılı TRAIL gen tedavi metodunun geliştirilmesi (2004)
    Uluslararası kongre, sempozyum, panel gibi bilimsel toplantılarda sunularak, programda yer alan poster bildiri
    1- Additional t(3;3)(q29;q23),t(4;11)(q21;q23), t(11;18)(q10;q10) translocations in a patient with chronic phase Ph+CML (2012)
    2- Analysis of molecular cytogenetic markers and clinical outcome in chronic lymphocytic leukemia and multiple myeloma with 17p deletion; a single center experience (2012)
    3- Cytogenetic and molecular cytogenetic findings in chronic lymphocytic leukemia; a single center experience (2012)
    4- Non-obese diabetes resistant (NOR) mice are extremely susceptible to the toxic effects of streptozotocin reflected by high Glut2 expressions in pancreas and liver (2014)
    5- A rare transformation case report: from Chronic Lymphocytic Leukemia to Multiple Myeloma (2014)
    6- An uncommon coincidation of multiple myeloma and myelodysplastic syndrome (2014)
    7- A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. (2007)
    8- Fundamental principles of tumor necrosis factor alpha gene therapy approach and implications for patients with lung carcinoma. (2007)
    9- A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. (2006)
    10- Surface TRAIL Decoy Receptor-4 expression constitutes a resistance to adenovirus delivery of TRAIL in MCF7 Breast Cancer cells. (2005)
    11- .A DcR2 siRNA approach overcomes TRAIL resistance in A549 lung cancer cells. (2005)
    12- Surface TRAIL Receptor-4 expression correlates with TRAIL resistance in breast cancer cells. (2005)
    13- A novel death ligand mediated gene therapy approach for patients with lung cancer. (2005)
    14- Fundamental principles of tumor necrosis factor alpha gene therapy approach and implications for patients with lung carcinoma. (2004)
    15- The therapeutical effect of recombinant adenovirus mediated TRAIL gene therapy method in lung cancer. (2004)
    Uluslararası kongrelerde sunulan ve özeti SCI, SSCI, AHCI tarafından taranan dergilerde yayımlanan bildiri
    1- Diabetogenic response to streptozotocin varies among NOD and NOR mice (2012)
    2- Pancreatic acinar cells respond differentially to diabetic agents streptozotocin and cyclophosphamide (2012)
    3- Trail profile of synoviocytes and peripheral blood lymphocytes of rheumatoid arthritis patients (2010)
    4- The importance of sTRAIL in patients with rheumatoid arthritis. (2010)
    5- . Endometrial hyperplasia features distinctive TRAIL and TRAIL receptor expression profiles. (2010)
    6- Distinctive expression profiles of TRAIL and TRAIL receptors in patients with endometrial carcinoma (2010)
    7- The outcome of TRAIL presentation on T cells in patients with multiple myeloma. (2010)
    8- Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. (2009)
    9- TRAIL death receptor-4 and decoy receptors expression on CD8+T cells correlate with the disease severity in rheumatoid arthritis patients. (2009)
    10- Tracing of the fate of allogeneic islet grafts via CCD camera (2009)
    11- Diagnostic significance of serum sTRAIL in rheumatoid arthritis (2009)
    12- Rheumatoid Arthritis disease activity is correlated with TRAIL death receptor-4 and decoy receptor expresions on CD8+ T cells. (2009)
    13- Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. (2009)
    14- DcR2 siRNA approach defeats TRAIL resistance in lung cancer cells. (2006)
    15- Monosomy 7 and ring/marker chromosome derived from chromosome 7 in a patient with MDS-RAEB-2: A case report (2015)
    16- Evaluation of TEL/AML1 fusion and additional abnormalities involving TEL and/or AML1 genes using FISH technique in patients with childhood acute lymphoblastic leukemia (2015)
    17- Evaluation of MDM2 gene copy number alterations in chronic lymphocytic leukemia patients with fluorescent in situ hybridization (2015)

    EDİTÖRLÜK


    HAKEMLİK


    İDARİ GÖREV ve TOPLUMSAL KATKILAR

    Dekan, enstitü yada yüksekokul müdür yardımcılığı; merkez müdürlüğü yada bölüm başkanlığı
    1- Bucak Sağlık Yüksekokulu, Müdür Yardımcılığı (Yıl:2015)

    SANAT ve TASARIM ETKİNLİKLERİ


    DİĞER

    Makaleler, Yazılar

    Kullanıcı herhangi bir makale, yazı paylaşmamış.

    Dosyalar

    Eklenmiş dosya bulunmamaktadır.

    Fotoğraflar

    Fotoğraf Eklenmemiş.

    Duyurular

    Herhangi bir duyuru bulunmamaktadır.

    Dersler

    Önlisans


    Lisans


    Lisanüstü

    İletişim

    İLETİŞİM FORMU ve BİLGİLERİ

    Telefon 2483259000 -129
    Email cacar(at)mehmetakif.edu.tr
    Adres


    Ad Soyad   
    Eposta  
    Yorum  
    4 + 13 = ?    İşlemin sonucunu giriniz.